Gene · 9833
Papers1,515
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,515
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Flavonoids as Dual Inhibitors of MELK and LYN Kinases in Cervical Cancer: An In Silico Molecular Docking Analysis. | Curr Pharm Des | 2026 | 40916411 | PubTator, text mining | PubMed |
In Silico Transcriptomic Analysis for Identification of Potential Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Cervical Cancer using a Hybrid Genetic Algorithm-Support Vector Machine Approach. | Arch Iran Med | 2025 | 41852002 | PubTator, text mining | PubMed |
| Exploratory research on therapeutic agents combined with early diagnostic biomarkers for colorectal cancer. | Front Pharmacol | 2025 | 41585903 | PubTator, text mining | PubMed |
| Differentially Expressed Genes Associated with the Development of Cervical Cancer. | Int J Mol Sci | 2025 | 41516135 | PubTator, text mining | PubMed |
| Computational identification of Moracin G and Isolonchocarpin as potent MELK inhibitors for anticancer drug discovery. | Sci Rep | 2025 | 41353459 | PubTator, text mining | PubMed |
| Melk facilitates pulmonary artery smooth muscle cell proliferation and migration in pulmonary hypertension via modulation of YAP/TAZ signaling. | Front Cell Dev Biol | 2025 | 41278210 | PubTator, text mining | PubMed |
| Taxonomic characterization and cytotoxic potential of Vietnamese Ganoderma ellipsoideum against human breast cancer MCF-7 cells. | PLoS One | 2025 | 41237100 | PubTator, text mining | PubMed |
Inhibitory potential of Malabaricone C and Quercetagetin against aberrantly expressed Maternal Embryonic Leucine Zipper Kinase using integrated virtual screening, molecular dynamics and MMGBSA approach. | In Silico Pharmacol | 2025 | 41211463 | PubTator, text mining | PubMed |
| Integrated Expression Analysis May Support Serine/Threonine Kinases as Common Hub Genes in Breast Cancer. | Iran J Med Sci | 2025 | 41158841 | PubTator, text mining | PubMed |
| A meta-learning framework to mitigate negative transfer in transfer learning applicable to drug design. | Sci Rep | 2025 | 41068285 | PubTator, text mining | PubMed |
| O-GlcNAcylation of UBAP2L regulates stress granule formation and sunitinib resistance in clear cell renal cell carcinoma. | J Exp Clin Cancer Res | 2025 | 41029457 | PubTator, text mining | PubMed |
| Bioinformatics analysis of immune infiltration and cell cycle hub genes in atopic dermatitis. | Biochem Biophys Rep | 2025 | 40989718 | PubTator, text mining | PubMed |
| CEACAM6 as a machine learning derived immune biomarker for predicting neoadjuvant chemotherapy response in HR+/HER2- breast cancer. | Front Immunol | 2025 | 40936892 | PubTator, text mining | PubMed |
| Exploring replication stress and cellular senescence as key targets in novel cancer therapies. | Cancer Genet | 2025 | 40934728 | PubTator, text mining | PubMed |
| Oleandrin-mediated suppression of MELK induces apoptosis, autophagy, and ferroptosis in human non-small cell lung cancer cells. | Phytomedicine | 2025 | 40916237 | PubTator, text mining | PubMed |
| Construction and Validation of a Novel Prognostic Model Based on Cervical Cancer-Related Genes. | Reprod Sci | 2025 | 40908400 | PubTator, text mining | PubMed |
| The balance between B55α and Greatwall expression levels predicts sensitivity to Greatwall inhibition in cancer cells. | Nat Commun | 2025 | 40866357 | PubTator, text mining | PubMed |
| Mechanism and cellular actions of the potent AMPK inhibitor BAY-3827. | Sci Adv | 2025 | 40845097 | PubTator, text mining | PubMed |
| Identification of biomarkers and potential therapeutic targets of breast cancer using bioinformatics analysis. | Medicine (Baltimore) | 2025 | 40826700 | PubTator, text mining | PubMed |
| Multi-Omics analysis and in vitro validation reveal diagnostic and therapeutic roles of novel hub genes in ovarian cancer. | Hereditas | 2025 | 40826138 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9833/papers?page=3